REDHILL B.S.ADR 10/IL-,01 WKN: A1KBQX ISIN: US7574681034 Kürzel: RDHL Forum: Aktien Thema: Hauptdiskussion

Mr. Ben-Asher continued: “Improved financial stability resulting from cost savings, a commercial basket including three FDA-approved proprietary drugs, continued prescription growth and healthy sales, improved managed care coverage and the amended credit agreement with HCR, positions RedHill for further growth. To that end, RedHill is in non-binding discussions to acquire a synergetic U.S. FDA-approved, patented GI drug currently generating dozens of millions of dollars, which, if materialized, will help expedite and increase cash generation.”

Dror Ben-Asher, RedHill’s Chief Executive Officer, said: “To address the current market realities and operating landscape, RedHill is being decisive about controlling its own destiny and is highly focused on achieving earlier profitability, targeting positive cash from operations to start during H2/22. Our comprehensive cost reduction plan is expected to generate operational cost savings of approximately $50 million over the next 18 months. The majority of these savings result from an approximately one-third reduction of the U.S. commercial team workforce, returning to pre-pandemic levels, streamlined operational expenditure including selling, general and administrative (SG&A) expenses and refining the Company’s R&D strategy to rely mostly on external funding sources based on the promising clinical data generated to date. On behalf of RedHill and its Board of Directors, I would like to express my profound and respectful gratitude to the colleagues who are departing RedHill. We value and are extremely grateful for your immense contributions and dedication which enabled RedHill to build a first-class U.S. commercial organization and launch three innovative products that help patients in need. While difficult, the changes we have made as part of our cost reduction plan were necessary given the current realities.”

Targeting positive cash from operations to start during H2/22 Focus on earlier achievement of operational profitability thanks to a recently implemented comprehensive cost reduction plan, with expected operational cost savings of approximately $50 million over the next 18 months Continuous implementation of disciplined cost controls reduced Q1/22 cash used in operating activities by more than 70% to approximately $4 million, compared to approximately $15 million in Q4/21 Net revenues of $18.2 million in Q1/22; Cash balance of $45 million as of March 31, 2022 Talicia® TRx up 12.8% over Q4/21 and Movantik® continues strong Q4/21 prescription performance Amendment improves key covenants in the HCR Credit Agreement Given encouraging data to date, opaganib and RHB-107 COVID-19 Phase 3-stage programs expected to be funded via external sources; Global and U.S. regulatory interactions ongoing Management to host webcast today, at 08:30 a.m. EDT

schätze das Insider wieder mehr wissen als wir und daher ab verkauf

Schließen wir wieder bei o 0,70 Cent. Es macht keinen Spaß mehr hier

Eine Stelle aus der News: redhill is in non-binding discussions to acquire a synergetic U.S. FDA approved patented GI drug currently generating dozens of millions of dollars which if materialized will help expedite and increase cash generation

Eine interessante "Corporate News" aus der DGAP.de News App: RedHill Biopharma veröffentlicht Highlights aus Q1/2022: Im Plan zu einem positiven operativen Cashflow in H2/22 http://www.dgap.de/dgap/News/?newsID=1600041

@quincy11 sicher niedriger als jetzt man kennt ja den premarket

Gewinn Mitnahme sind das. Bin gespannt wo das heute Abend endet.

@Bunga: Für die Shorties ist das keine Gefahr, für uns ist das ein durchaus realitätsnahes Szenario.

Ja danke .

Das hat nichts mit „Shorties“ zu tun, wenn Gewinnmitnahmen erfolgen. Aber das ist ja bei Börsennews der neueste Trend einen Kursrückgäng auf Shortselling zu schieben.

Wie hoch ist die Gefahr, dass die Shorties sich Heute Mal so richtig die Taschen füllen?

👀